Prevalent oral human papillomavirus 16 infections in men persist longer than newly acquired infections, and the rate of persistence for incident infec... More »
Gilead Sciences Inc. scored an exclusive deal with CVS Health Corp., as its two hepatitis C medicines, Harvoni and Sovaldi, will be available only for CVS customers.
Sovaldi costs $84,000 for a...
By mapping the testing and care of patients with the hepatitis C virus on a continuum, health care providers can get a better picture of the stages at which the disease is being managed effectively...
PHILADELPHIA – Clostridium difficile infections among nursing home residents resulted in some 31,000 hospitalizations and 9,000 deaths nationally in 2012, population-based surveillance data...
AUSTIN, TEX. – Use of acid-suppressing drugs was associated with more severe presentation, longer hospital stay, and increased mortality among patients with community-acquired pneumonia presenting to...
Sofosbuvir plus GS-5816 appears to be a promising treatment regimen for treatment-naive patients with chronic genotype 1-6 hepatitis C virus infection without cirrhosis, according to a new study....
BOSTON – All but 1 of 51 patients who failed sofosbuvir-containing treatment regimens for hepatitis C achieved a sustained virologic response for 12 weeks after retreatment with ledipasvir and...
BOSTON – Screening all adults born between 1945 and 1965 for hepatitis C and then treating all infected patients with oral drug regimens is the most cost effective strategy for society, because...
BOSTON – Treating hepatitis C with a combination of ledipasvir and sofosbuvir produced a sustained virologic response in 49 of 50 patients coinfected with genotype 1 hepatitis C and HIV...
BOSTON – Since their approval in late 2013, the direct-acting antiviral agents sofosbuvir and simeprevir have taken over treatment of hepatitis C with real-world success that approximates clinical...